ALZHEIMER?S DISEASE RESEARCH CENTER

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：确定新的诊断测试和潜在的治疗方法，用于在患者没有临床症状的阶段（临床前阶段）预防阿尔茨海默病。 2009年5月，老年医学和老年学教授、老年医学研究、教育和临床中心（GRECC）主任Sanjay Asthana获得了一笔为期五年的690万美元的国家老龄研究所赠款，用于启动威斯康星州阿尔茨海默病研究中心（ADRC）。 这个新中心将建立在威斯康星大学麦迪逊分校卓越的神经科学研究的优势之上，为阿尔茨海默病（AD）和相关疾病提供最先进的资源，基础设施和专业知识。该中心主要关注AD的临床前和早期诊断和进展，将扩大威斯康星州阿尔茨海默病预防登记处的科学目标，并显着加强对患有AD疾病的威斯康星州居民的护理。 ADRC将由六个核心组成：行政，临床，数据管理和生物统计，神经病理学和生物标志物，教育和转移以及少数民族招聘卫星计划。该中心将建立在非常成功的华盛顿大学AD研究计划和最近的几个融合发展的基础上：这些包括华盛顿大学领导对AD的新关注，对AD研究的大量机构和国家财政承诺，华盛顿大学校园内几个著名的神经科学项目的存在，杰出的华盛顿大学临床项目，广泛的痴呆症诊断诊所全州网络，获得少数民族，低收入和农村人口通过少数民族招聘卫星计划（MRSP），承认几个UW研究人员在AD研究中的地位，以及众多UW中心和机构在老龄化和神经科学研究之间的密切合作。 参与的中心和研究所包括威斯康星州阿尔茨海默氏症研究所、老龄研究所、威斯康星大学韦斯曼中心、威斯康星大学韦斯曼脑成像和行为实验室、NIH/CTSA资助的临床和转化研究所（ICTR）、威斯康星州国家灵长类动物研究中心、生物技术中心、基因组中心、临床和转化研究中心（以前称为UW GCRC）和麦迪逊退伍军人事务部（VA）老年医学研究、教育和临床中心（GRECC）。鉴于获得优秀的资源和专业知识，威斯康星州ADRC已准备好作出新的贡献，AD研究领域，并提供出色的临床护理，从疾病的患病患者。 威斯康星州ADRC的主要重点是确定新的诊断测试和潜在的治疗方法，用于在患者没有临床症状的阶段（临床前阶段）预防阿尔茨海默病。Asthana的团队预计，这种疗法将有助于减少患阿尔茨海默病的人数。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To identify novel diagnostic tests and potential therapies for the prevention of Alzheimer's disease at a stage when patients have no clinical symptoms (preclinical stage). Sanjay Asthana, professor of geriatrics and gerontology, and director of the Geriatric Research, Education and Clinical Center (GRECC), in May 2009 landed a five-year $6.9 million National Institutes on Aging grant to launch the Wisconsin Alzheimer's Disease Research Center (ADRC). This new center will build upon the strengths of UW-Madison's remarkable neuroscience research to provide state-of-the-art resources, infrastructure, and expertise in Alzheimer's disease (AD) and related illnesses. With the major focus on preclinical and early diagnosis and progression of AD, the center will expand the scientific objectives of the Wisconsin Registry for Alzheimer's Prevention and significantly enhance care of Wisconsin residents suffering from the devastations of AD. The ADRC will be comprised of six cores: Administrative, Clinical, Data Management and Biostatistics, Neuropathology and Biomarkers, Education and Transfer and the Minority Recruitment Satellite Program. The center will build upon the highly successful UW research program in AD and several recent convergent developments: These include a new focus of the UW leadership on AD, substantial institutional and state financial commitment to AD research, presence of several renowned programs in neuroscience on the UW campus, outstanding UW clinical programs, an extensive statewide network of dementia diagnostic clinics, access to minority, low-income and rural populations through the Minority Recruitment Satellite Program (MRSP), acknowledged status of several UW investigators in AD research, and close collaborations between numerous UW centers and institutes in aging and neuroscience research. The involved centers and institutes include the Wisconsin Alzheimer's Institute, Institute on Aging, UW Waisman Center, UW Waisman Laboratory for Brain Imaging and Behavior, NIH/CTSA-funded Institute for Clinical and Translational Research (ICTR), Wisconsin National Primate Research Center, Biotechnology Center, Genome Center, Clinical and Translational Research Core (formerly known as the UW GCRC), and Madison Veterans Affairs (VA) Geriatric Research, Education and Clinical Center (GRECC). Given the access to outstanding resources and expertise, the Wisconsin ADRC is well poised to make novel contributions to the field of AD research and provide outstanding clinical care to patients suffering from the devastations of the disease. The major focus of the Wisconsin ADRC is to identify novel diagnostic tests and potential therapies for the prevention of Alzheimer's disease at a stage when patients have no clinical symptoms (preclinical stage). Asthana's team anticipates that such therapies will help reduce the number of individuals suffering from Alzheimer's disease.